Press Releases

January 08, 2021
CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference
December 23, 2020
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation
December 16, 2020
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
November 18, 2020
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)
November 09, 2020
CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results
November 05, 2020
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020
October 27, 2020
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
October 02, 2020
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting
September 29, 2020
CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd
September 11, 2020
CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences
August 10, 2020
CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results
August 03, 2020
CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020
July 22, 2020
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock
July 21, 2020
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
June 08, 2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
June 02, 2020
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
May 11, 2020
CASI Pharmaceuticals Announces First Quarter 2020 Financial Results
April 07, 2020
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
March 16, 2020
CASI Pharmaceuticals Announces Full Year 2019 Financial Results
December 03, 2019
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

Page 2 of 14 pages < 1 2 3 4 > Last ›

INVESTOR CONTACT:

Jennifer Porcelli
Solebury Trout
740 Broadway
New York, NY 10003

Ph: 646.378.2962
Email: jporcelli@troutgroup.com

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Downloads

Corporate Presentation

EVOMELA^® (melphalan) for Injection, ZEVALIN^® (ibritumomab tiuxetan), and MARQIBO^® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.

CASI Pharmaceuticals

© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.